ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
We analyzed deidentified data from an EHR-derived database for patients with advanced non–small cell lung cancer (aNSCLC) at their first line of treatment. Our novel imputation method involved (1) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results